Search Results - "Damrauer, Jeffrey S."

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology by Damrauer, Jeffrey S., Hoadley, Katherine A., Chism, David D., Fan, Cheng, Tiganelli, Christopher J., Wobker, Sara E., Yeh, Jen Jen, Milowsky, Matthew I., Iyer, Gopa, Parker, Joel S., Kim, William Y.

“…We sought to define whether there are intrinsic molecular subtypes of high-grade bladder cancer. Consensus clustering performed on gene expression data from a…”
Get full text

CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors by Walens, Andrea, DiMarco, Ashley V, Lupo, Ryan, Kroger, Benjamin R, Damrauer, Jeffrey S, Alvarez, James V

“…Over half of breast-cancer-related deaths are due to recurrence 5 or more years after initial diagnosis and treatment. This latency suggests that a population…”
Get full text

FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer by Arceci, Anthony, Bonacci, Thomas, Wang, Xianxi, Stewart, Kyle, Damrauer, Jeffrey S., Hoadley, Katherine A., Emanuele, Michael J.

“…The transcription factor FOXM1 contributes to cell cycle progression and is significantly upregulated in basal-like breast cancer (BLBC). Despite its…”
Get full text

Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy by Saito, Ryoichi, Smith, Christof C, Utsumi, Takanobu, Bixby, Lisa M, Kardos, Jordan, Wobker, Sara E, Stewart, Kyle G, Chai, Shengjie, Manocha, Ujjawal, Byrd, Kevin M, Damrauer, Jeffrey S, Williams, Scott E, Vincent, Benjamin G, Kim, William Y

“…High-grade urothelial cancer contains intrinsic molecular subtypes that exhibit differences in underlying tumor biology and can be divided into luminal-like…”
Get full text

Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence by Walens, Andrea, Lin, Jiaxing, Damrauer, Jeffrey S., McKinney, Brock, Lupo, Ryan, Newcomb, Rachel, Fox, Douglas B., Mabe, Nathaniel W., Gresham, Jeremy, Sheng, Zhecheng, Sibley, Alexander B., De Buysscher, Tristan, Kelkar, Hemant, Mieczkowski, Piotr A., Owzar, Kouros, Alvarez, James V.

“…The survival and recurrence of residual tumor cells following therapy constitutes one of the biggest obstacles to obtaining cures in breast cancer, but it…”
Get full text

Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer by Damrauer, Jeffrey S., Beckabir, Wolfgang, Klomp, Jeff, Zhou, Mi, Plimack, Elizabeth R., Galsky, Matthew D., Grivas, Petros, Hahn, Noah M., O’Donnell, Peter H., Iyer, Gopa, Quinn, David I., Vincent, Benjamin G., Quale, Diane Zipursky, Wobker, Sara E., Hoadley, Katherine A., Kim, William Y., Milowsky, Matthew I.

“…Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and Research (NCT02643043), UC-GENOME, is a genomic analysis and biospecimen repository study…”
Get full text

Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia by Damrauer, Jeffrey S., Stadler, Michael E., Acharyya, Swarnali, Baldwin, Albert S., Couch, Marion E., Guttridge, Denis C.

“…A compounding feature of greater than 50% of all cancers is the high incidence of the cachexia syndrome, a complex metabolic disorder characterized by extreme…”
Get full text

Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer by Beckabir, Wolfgang, Zhou, Mi, Lee, Jin Seok, Vensko, Steven P., Woodcock, Mark G., Wang, Hsing-Hui, Wobker, Sara E., Atassi, Gatphan, Wilkinson, Alec D., Fowler, Kenneth, Flick, Leah M., Damrauer, Jeffrey S., Harrison, Michael R., McKinnon, Karen P., Rose, Tracy L., Milowsky, Matthew I., Serody, Jonathan S., Kim, William Y., Vincent, Benjamin G.

“…Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in…”
Get full text

Development and validation of a NanoString BASE47 bladder cancer gene classifier by Kardos, Jordan, Rose, Tracy L, Manocha, Ujjawal, Wobker, Sara E, Damrauer, Jeffrey S, Bivalaqua, Trinity J, Kates, Max, Moore, Kristin J, Parker, Joel S, Kim, William Y

“…Recent molecular characterization of urothelial cancer (UC) has suggested potential pathways in which to direct treatment, leading to a host of targeted…”
Get full text

Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer by Carper, Miranda B., Goel, Saumya, Zhang, Anna M., Damrauer, Jeffrey S., Cohen, Stephanie, Zimmerman, Matthew P., Gentile, Gabrielle M., Parag-Sharma, Kshitij, Murphy, Ryan M., Sato, Kotaro, Nickel, Kwangok P., Kimple, Randall J., Yarbrough, Wendell G., Amelio, Antonio L.

“…Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide and incidence rates are continuing to rise globally. Patients often…”
Get full text

Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal by Zhou, Bing, Damrauer, Jeffrey S, Bailey, Sean T, Hadzic, Tanja, Jeong, Youngtae, Clark, Kelly, Fan, Cheng, Murphy, Laura, Lee, Cleo Y, Troester, Melissa A, Miller, C Ryan, Jin, Jian, Darr, David, Perou, Charles M, Levine, Ross L, Diehn, Maximilian, Kim, William Y

“…Erythropoietin (EPO) is a hormone that induces red blood cell production. In its recombinant form, EPO is the one of most prescribed drugs to treat anemia,…”
Get full text

mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma by Bailey, Sean T, Zhou, Bing, Damrauer, Jeffrey S, Krishnan, Bhavani, Wilson, Harper L, Smith, Aleisha M, Li, Mingqing, Yeh, Jen Jen, Kim, William Y

“…Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of…”
Get full text

Genomic characterization of rare molecular subclasses of hepatocellular carcinoma by Damrauer, Jeffrey S., Smith, Markia A., Walter, Vonn, Thennavan, Aatish, Mose, Lisle E., Selitsky, Sara R., Hoadley, Katherine A.

“…Primary liver cancer, consisting of both cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC), is the second leading cause of cancer deaths worldwide…”
Get full text

Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer by Robertson, A. Gordon, Yau, Christina, Carrot-Zhang, Jian, Damrauer, Jeffrey S., Knijnenburg, Theo A., Chambwe, Nyasha, Hoadley, Katherine A., Kemal, Anab, Zenklusen, Jean C., Cherniack, Andrew D., Beroukhim, Rameen, Zhou, Wanding

“…Cellular and molecular aberrations contribute to the disparity of human cancer incidence and etiology between ancestry groups. Multiomics profiling in The…”
Get full text

Analytical protocol to identify local ancestry-associated molecular features in cancer by Carrot-Zhang, Jian, Han, Seunghun, Zhou, Wanding, Damrauer, Jeffrey S., Kemal, Anab, Berger, Ashton C., Meyerson, Matthew, Hoadley, Katherine A., Felau, Ina, Caesar-Johnson, Samantha, Demchok, John A., Mensah, Michael K.A., Tarnuzzer, Roy, Wang, Zhining, Yang, Liming, Zenklusen, Jean C., Chambwe, Nyasha, Knijnenburg, Theo A., Robertson, A. Gordon, Yau, Christina, Benz, Christopher, Huang, Kuan-lin, Newberg, Justin, Frampton, Garret, Mashl, R. Jay, Ding, Li, Romanel, Alessandro, Demichelis, Francesca, Sayaman, Rosalyn W., Ziv, Elad, Laird, Peter W., Shen, Hui, Wong, Christopher K., Stuart, Joshua M., Lazar, Alexander J., Le, Xiuning, Oak, Ninad, Cherniack, Andrew D., Beroukhim, Rameen

“…People of different ancestries vary in cancer risk and outcome, and their molecular differences may indicate sources of these variations. Determining the…”
Get full text

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer by Carrot-Zhang, Jian, Chambwe, Nyasha, Damrauer, Jeffrey S., Knijnenburg, Theo A., Robertson, A. Gordon, Yau, Christina, Zhou, Wanding, Berger, Ashton C., Huang, Kuan-lin, Newberg, Justin Y., Mashl, R. Jay, Romanel, Alessandro, Sayaman, Rosalyn W., Demichelis, Francesca, Felau, Ina, Frampton, Garrett M., Han, Seunghun, Hoadley, Katherine A., Kemal, Anab, Laird, Peter W., Lazar, Alexander J., Le, Xiuning, Oak, Ninad, Shen, Hui, Wong, Christopher K., Zenklusen, Jean C., Ziv, Elad, Aguet, Francois, Ding, Li, Demchok, John A., Mensah, Michael K.A., Caesar-Johnson, Samantha, Tarnuzzer, Roy, Wang, Zhining, Yang, Liming, Alfoldi, Jessica, Karczewski, Konrad J., MacArthur, Daniel G., Meyerson, Matthew, Benz, Christopher, Stuart, Joshua M., Cherniack, Andrew D., Beroukhim, Rameen

“…We evaluated ancestry effects on mutation rates, DNA methylation, and mRNA and miRNA expression among 10,678 patients across 33 cancer types from The Cancer…”
Get full text

Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling by Chandler, Ronald L., Damrauer, Jeffrey S., Raab, Jesse R., Schisler, Jonathan C., Wilkerson, Matthew D., Didion, John P., Starmer, Joshua, Serber, Daniel, Yee, Della, Xiong, Jessie, Darr, David B., de Villena, Fernando Pardo-Manuel, Kim, William Y., Magnuson, Terry

“…Ovarian clear-cell carcinoma (OCCC) is an aggressive form of ovarian cancer with high ARID1A mutation rates. Here we present a mutant mouse model of OCCC. We…”
Get full text

B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres by Nehama, Dean, Di Ianni, Natalia, Musio, Silvia, Du, Hongwei, Patané, Monica, Pollo, Bianca, Finocchiaro, Gaetano, Park, James J.H., Dunn, Denise E., Edwards, Drake S., Damrauer, Jeffrey S., Hudson, Hannah, Floyd, Scott R., Ferrone, Soldano, Savoldo, Barbara, Pellegatta, Serena, Dotti, Gianpietro

“…The dismal survival of glioblastoma (GBM) patients urgently calls for the development of new treatments. Chimeric antigen receptor T (CAR-T) cells are an…”
Get full text

Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer by Beckabir, Wolfgang, Wobker, Sara E., Damrauer, Jeffrey S., Midkiff, Bentley, De la Cruz, Gabriela, Makarov, Vladmir, Flick, Leah, Woodcock, Mark G., Grivas, Petros, Bjurlin, Marc A., Harrison, Michael R., Vincent, Benjamin G., Rose, Tracy L., Gupta, Shilpa, Kim, William Y., Milowsky, Matthew I.

“…Digital spatial profiling of muscle-invasive bladder cancer tumors demonstrated that associations of tumor and immunobiology protein markers with neoadjuvant…”
Get full text

FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression by Okato, Atsushi, Utsumi, Takanobu, Ranieri, Michela, Zheng, Xingnan, Zhou, Mi, Pereira, Luiza D, Chen, Ting, Kita, Yuki, Wu, Di, Hyun, Hyesun, Lee, Hyojin, Gdowski, Andrew S, Raupp, John D, Clark-Garvey, Sean, Manocha, Ujjawal, Chafitz, Alison, Sherman, Fiona, Stephens, Janaye, Rose, Tracy L, Milowsky, Matthew I, Wobker, Sara E, Serody, Jonathan S, Damrauer, Jeffrey S, Wong, Kwok-Kin, Kim, William Y

“…The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of intense interest. We studied the interaction of fibroblast growth…”
Get full text